Table 3. Clinical recommendations for... | American Society of Hematology

Table 3.

Clinical recommendations for assessing cardiotoxicity in patients with CML receiving TKI treatment

Assessment	Imatinib	Bosutinib	Dasatinib	Nilotinib	Ponatinib
Baseline assessment
Cardiovascular assessment	X	X	X	X	X
Blood pressure check	X	X	X	X	X
Fasting glucose	+	+	+	X	X
Fasting lipid panel	+	+	+	X	X
Echocardiogram	+	+	+*	+	+
Electrocardiogram	X	X	X	X	X
Ankle–brachial index	+	+	+	X	X
1-mo follow-up
Cardiovascular assessment	+	+	X	X	X
Blood pressure check	+	+	+	+	X
3- to 6-mo follow-up
Cardiovascular assessment	X	X	X	X	X
Blood pressure check	+	+	+	X	X
Fasting glucose	+	+	+	X	+
Fasting lipid panel	+	+	+	X	X
Echocardiogram	+	+	+*	+	+
Electrocardiogram	+	+	+	X	X
Ankle–brachial index	+	+	+	X	X

Assessment	Imatinib	Bosutinib	Dasatinib	Nilotinib	Ponatinib
Baseline assessment
Cardiovascular assessment	X	X	X	X	X
Blood pressure check	X	X	X	X	X
Fasting glucose	+	+	+	X	X
Fasting lipid panel	+	+	+	X	X
Echocardiogram	+	+	+*	+	+
Electrocardiogram	X	X	X	X	X
Ankle–brachial index	+	+	+	X	X
1-mo follow-up
Cardiovascular assessment	+	+	X	X	X
Blood pressure check	+	+	+	+	X
3- to 6-mo follow-up
Cardiovascular assessment	X	X	X	X	X
Blood pressure check	+	+	+	X	X
Fasting glucose	+	+	+	X	+
Fasting lipid panel	+	+	+	X	X
Echocardiogram	+	+	+*	+	+
Electrocardiogram	+	+	+	X	X
Ankle–brachial index	+	+	+	X	X

Assessments are done at baseline, 1-mo follow-up, and 3- to 6-month follow-up. CV screening should be considered for periods beyond 6 mo in all patients, but particularly for high-risk patients. +, as clinically indicated; CML, chronic myeloid leukemia; CV, cardiovascular; X, recommended; TKI, tyrosine kinase inhibitor.

Patients treated with dasatinib should be considered for an echocardiogram if cardiopulmonary symptoms are present.

View Large

This Feature Is Available To Subscribers Only